Cargando…

Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database

Objective: This study aims to explore the risk signals of osteonecrosis of the jaw induced by antiresorptive drugs and provide references for the clinical safety application. Method: According to the FDA’s Adverse Event Reporting System (FAERS), from January 2004 to September 2021, we chose “Osteone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jing, Wang, Hui, Liu, Zhen, Xu, Zhen-Liang, Wang, Mei-Xia, Chen, Qi-Miao, Wu, Ming-Li, Ren, Xiao-Lei, Liang, Qiu-Hua, Liu, Fu-Peng, Ban, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627332/ https://www.ncbi.nlm.nih.gov/pubmed/36339548 http://dx.doi.org/10.3389/fphar.2022.1017391

Ejemplares similares

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw
por: Kim, Ha Young
Publicado: (2021)

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries
por: Taguchi, Akira, et al.
Publicado: (2017)

Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication)()
por: Baba, Akira, et al.
Publicado: (2019)

The risk of osteonecrosis of the jaw and adverse outcomes in patients using antiresorptive drugs undergoing orthodontic treatment: A systematic review
por: Woolley, Julian, et al.
Publicado: (2021)

Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature
por: Pimolbutr, Kununya, et al.
Publicado: (2018)

Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?
por: Oteri, Giacomo, et al.
Publicado: (2018)

Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS
por: Anastasilakis, Athanasios D, et al.
Publicado: (2021)

Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan
por: Kunihara, Takahiro, et al.
Publicado: (2023)

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review
por: Sacco, Roberto, et al.
Publicado: (2021)

The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis
por: Aboalela, Ali A, et al.
Publicado: (2022)

The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw
por: Chin, Kok-Yong, et al.
Publicado: (2022)

Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage
por: Watanabe, Takuma, et al.
Publicado: (2021)

Relationship between Drug Holidays of Antiresorptive Agents and Surgical Outcomes in Cancer Patients with Medication-Related Osteonecrosis of the Jaw
por: Otsuru, Mitsunobu, et al.
Publicado: (2022)

Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis
por: Srivastava, Akanksha, et al.
Publicado: (2021)

Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients
por: Morishita, Kota, et al.
Publicado: (2022)

Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan
por: Nashi, Masanori, et al.
Publicado: (2023)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
por: Jung, Sung-mok, et al.
Publicado: (2018)

Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database
por: Inada, Ayaka, et al.
Publicado: (2018)

Predictive Value of Neutrophil–Lymphocyte Ratio as a Marker in Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Retrospective Analysis
por: Kurohara, Kazuto, et al.
Publicado: (2022)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review
por: Wang, Feng, et al.
Publicado: (2022)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency
por: Dalle Carbonare, Luca, et al.
Publicado: (2021)

Genome-wide association study of osteonecrosis of the jaw in Danish patients receiving antiresorptive therapy for osteoporosis: A case-control study
por: Pedersen, Alma B., et al.
Publicado: (2022)

Medication‐related osteonecrosis of the jaw and successful implant treatment in a patient on high‐dose antiresorptive medication: A case report
por: Ottesen, Camilla, et al.
Publicado: (2022)

Histopathological findings affect quantitative values of single photon emission computed tomography in patients with antiresorptive agent-related osteonecrosis of the jaws
por: Okui, Taro, et al.
Publicado: (2023)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience
por: Favia, Gianfranco, et al.
Publicado: (2016)

Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
por: Ottesen, Camilla, et al.
Publicado: (2020)

Intraoral localized methotrexate‐associated lymphoproliferative disorders concurrent with antiresorptive agent‐related osteonecrosis of the jaw: A case report and literature review
por: Minabe, Masaki, et al.
Publicado: (2020)

Response to Letter to the Editor From Taguchi: “Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS”
por: Anastasilakis, Athanasios D, et al.
Publicado: (2022)

Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events
por: Acquavella, John, et al.
Publicado: (2016)

Osteonecrosis of the Jaw
por: Lončar Brzak, Božana, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
por: Sankar, Pramod S, et al.
Publicado: (2018)

Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bian, Sainan, et al.
Publicado: (2021)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database
por: Toriumi, Shinya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_db67frunpvsm3cse122v8b7tg9